| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Marketing > American Demographics |
|
Advice You - American Demographics
Considering the vastness of the topic of American demographics, it is convenient to limit discu According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ssions on the subject to the demographic field of American population. American demographics gi ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in e in-depth estimates of all the major trends of the nation, as well as the regions of the count lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. y. These demographic reports, as already mentioned, cover all the statistical data of the nati here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe n’s economy, social customs, religion, ethnicity, race, market, consumption modes, food habits, d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro clothing, homes, population, mortality and fertility rates, and other such records. These repor ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc s are based on a given time period. According to the recent demographic report, the population easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi f the United States is 288,368,698, and this report is based on the estimation of the Census Bu nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically eau. This report covers the period through July 2002. American demographics, when it provides and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ uch data, also help us to acquire other key information and the status of various developments. ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi One can extract other data by simply implementing various statistical tools. For example, from ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a the above population report of the United States, one can draw the general rate of increase unt dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod l July 2002 from a particular point of time. In this case, one can conclude that there is a sh cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin rp rise in population by 2.47% simply by getting back to the data of July 2000 which showed the tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen population to be 281,421,906. The ten most populous cities in America, according to the 2000 c t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel nsus, are: 1. New York City, New York 8,017,078 2. Los Angeles, California 3,703 ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust 930 3. Chicago, Illinois 2,895,444 4. Houston, Texas 1, y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products 58,258 5. Philadelphia, Pennsylvania 1,513,684 6. Phoenix, Arizona 1,325, . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de 15 7. San Diego, California 1,228,196 8. Dallas, Texas 1,190 elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip 334 9. San Antonio, Texas 1,154,897 10. San Jose, California 945,00 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Medical Billing - DME Software Navigation Do You Know What Your Employees Are Doing? Beat Sunday Anxiety/Workplace Blues with a Dramatic Career Change
|